Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer.
Liu S, Zou Q, Chen JP, Yao X, Guan P, Liang W, Deng P, Lai X, Yin J, Chen J, Chen R, Yu Z, Xiao R, Sun Y, Hong JH, Liu H, Lu H, Chen J, Bei JX, Koh J, Chan JY, Wang B, Kang T, Yu Q, Teh BT, Liu J, Xiong Y, Tan J.
Liu S, et al. Among authors: lai x.
J Clin Invest. 2021 Oct 15;131(20):e145035. doi: 10.1172/JCI145035.
J Clin Invest. 2021.
PMID: 34464356
Free PMC article.